[CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer].
The exact classification of clinically significant versus insignificant prostate cancer displays one of major problems in current urological practice. Using novel molecular biomarkers, we are trying to decrease overdiagnosis of insignificant cancer. CpG island hypermethylation as a common epigenetic event is a well-recognized phenomenon during carcinogenesis. We have shown that hypermethylation at several gene loci distinguishes between benign and malignant forms of prostatic disorders. Furthermore using tests in cancer tissue and serum samples, one can draw prognostic conclusions and predict biochemical failure following radical prostatectomy with curative intent.
Bastian
P J
PJ
Urologische Klinik und Poliklinik,Klinikum der Universität München-Grosshadern, Ludwig-Maximilians-Universität München, München, Deutschland. patrick.bastian@med.uni-muenchen.de
Ellinger
J
J
von Rücker
A
A
Müller
S C
SC
Yegnasubramanian
S
S
Nelson
W G
WG
Stief
C G
CG
D002471:Cell Transformation, Neoplastic / Q000235:genetics; D018899:CpG Islands / Q000235:genetics*; D019175:DNA Methylation / Q000235:genetics*; D003937:Diagnosis, Differential; D044127:Epigenesis, Genetic / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics*; D005820:Genetic Testing; D051549:Glutathione S-Transferase pi / Q000235:genetics; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics*; D012307:Risk Factors
D005819:Genetic Markers; C496556:GSTP1 protein, human; D051549:Glutathione S-Transferase pi